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abstract
Imaging data have the potential to provide information on disease proﬁling
pertaining to diagnosis, prognosis, selection of therapy, monitoring of response to
therapy and pharmacokinetic information of drugs. Selection of the most appropriate
imaging modality for a speciﬁc task will be vital for diagnosis, stratiﬁcation,
treatment response or treatment efﬁcacy, toxicity assessment, and treatment
outcomemeasures (progression-free survival). The EORTC Imaging Group was formed
to establish and maintain the scientiﬁc and clinical value of advanced imaging in
EORTC clinical trials. The group focuses on the development of speciﬁc analytical
and review procedures as well as quality control procedures, in the context of clinical
trials conducted by the EORTC groups.
© 2012 European Organisation for Research and Treatment of Cancer.
1. Introduction and history
Imaging data have the potential to provide information
on disease proﬁling pertaining to diagnosis, selection of
therapy and monitoring of response to therapy as well
as providing information on the prognosis of patient and
pharmacokinetic information of drugs.
The EORTC Imaging Group (EORTC IG) traces its roots
to the EORTC PET (positron emission tomography) Study
Group which was created in 1994. In recognition of
equivalent needs in functional Magnetic Resonance
Imaging (MRI), the EORTC Functional Imaging Group was
formed in 2000, and published EORTC guidelines for the
use of FDG-PET in assessing response to therapy.
* Corresponding author. John Bean, EORTC Headquarters,
Avenue E. Mounier 83/11, 1200 Brussels, Belgium.
E-mail address: john.bean@eortc.be (J. Bean).
In 2009, the EORTC IG was founded to ensure stan-
dardization of image acquisition and quality assurance
for EORTC clinical trials for computed tomography (CT),
PET, MRI, and newer imaging modalities as they become
available. The group aims to increase molecular and
functional imaging, i.e. PET/CT and MRI, expertise
across the network, and identify and evaluate predictive
and prospective imaging biomarkers of interest in
multicenter clinical trials. This should enable more
robust planning of treatment such as image-guided
radiotherapy (IGRT). The goal of the group is also
to guarantee that scientiﬁcally interesting imaging
questions can be implemented in EORTC clinical trials.
The EORTC IG has set up several committees to
assist in achieving these objectives in EORTC multicenter
clinical trials: (1) The Clinical Trials Advisory Committee
(multimodality) ensures optimal use of multimodal
imaging technology through interaction with disease-
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oriented groups, protocol optimization, central review,
and development of a platform for centralized data
storage and analysis. (2) The Nuclear Medicine Technolo-
gies Committee ensures optimal use, quality assurance,
standardization, and harmonization of nuclear medicine
imaging. (3) The Radiology Technologies Committee
ensures optimal use, quality assurance, and standardiza-
tion of CT, MRI, and Ultrasound. (4) The Imaging in Radio-
therapy Committee (multimodality) aims to incorporate
advances in imaging technologies into radiotherapy, in-
cluding radiotherapy planning, response assessment and
distinguishing between disease progression and normal
tissue toxicity, and establish bridges with the radiation
oncology community. Finally, (5) The Education and
Training Committee aims to increase imaging expertise
across the network through training, standardization of
central reading, and eLearning.
2. An approach to standardizing imaging readouts
for use in multicenter trials: The EORTC, EANM,
EARL Quantitative PET Imaging accreditation
program
In PET imaging, optimal image quality is essential both
for visual interpretation as well as for quantiﬁcation.
Standardization of acquisition, reconstruction, interpre-
tation and quantiﬁcation of the images ensures high-
quality data across different imaging sites in multicenter
clinical trials. 1 Quantiﬁcation of FDG PET/CT studies is
usually performed by Standardized UptakeValues (SUVs).
SUV is deﬁned as the average activity concentration at
time t (measured in kBecquerels/mL) divided by dose
at time of injection (in MBecquerels) per body mass
(in kg). However, other normalizations, such as lean body
mass and body surface area can be used. Apart from
normalization, a number of factors − both technical and
biological − can affect image quality and quantiﬁcation,
such as hardware, volume of interest deﬁnition and
plasma glucose, so that standardized methods of
obtaining SUV are currently under discussion.
Technical factors that affect SUV are hardware or
methodology related. Inter-scanner variability up to 6%
over scanners of the same model has been observed. 2
In a double baseline study, variation in scanner
performance over time has shown 10.7% differences in
SUVmax, 3 calibration between PET scanner and dose
calibrator up to 10%, 4 residual activity in syringe and
tubing, timing mismatch up to 9.5% for 15 minutes, 5
inter-observer variability up to 17%, 6 choice of back-
ground for normalization, and quality of administration.
Methodology-related factors include scan acquisition
parameters, image reconstruction settings (up to 50%),
use of contrast agents up to 5.9%, 7 and ROI (region
of interest) or VOI (volume of interest) deﬁnitions.
Variability introduced by biological factors includes
uptake time which for high-grade tumors can be as
much as 30%, 8 motion from gross patient movement
and respiration, blood glucose levels, change in patient
weight during treatment, and body fat composition. A
minimum standard for acquisition, reconstruction and
interpretation of PET scans in multicenter clinical trials
setting therefore is necessary.
In addition to standardization alone, as FDG PET/CT
quantiﬁcation depends strongly on spatial resolution of
the reconstructed PET images, multicenter quantitative
PET studies require harmonization of image character-
istics. Harmonization aims at minimizing inter-scanner
and inter-institute differences in image quality and
quantiﬁcation by means of acquiring data with identical
spatial resolution. The European Association of Nuclear
Medicine (EANM) guideline for quantitative FDG PET/CT
studies therefore provides minimal standards for patient
preparation and scan acquisition, and proposes speciﬁc
quality control (QC) measures for harmonizing scanner
performance. The proposed multicenter QC program
aims at veriﬁcation of PET/CT system calibration, image
quantiﬁcation, and tracks the scanner performance.
Experiments are based on a uniform cylindrical phantom
(15−30 cm diameter) for scanner calibration veriﬁcation
and an adjusted NEMA NU 2-2001 image quality (IQ)
phantom to measure (and optimize) SUV recovery
coefﬁcients as a function of sphere size (reﬂecting
effective image resolution).
In order to implement the EANM guideline and
the QC procedures, an accreditation program was
set up and run under the direction of EARL (EANM
Research Ltd.) and the EORTC. The accreditation program
is based on QC experiments as described in the EANM
guideline. Manuals, SOPs and online questionnaires were
completed in August 2010 and training of an EARL
coordinator was provided in September 2010. To further
facilitate and standardize the accreditation program,
dedicated software tools for automated analysis of
the QC experiments were developed. These tools
allow automatic VOI (volume of interest) placement,
veriﬁcation of calibration, and veriﬁcation of inter- and
intra-plane uniformity. The image quantiﬁcation QC
software includes automated assessment of volume and
SUV recovery coefﬁcients, cold spot recovery using a
central insert to verify accuracy of scatter correction,
and veriﬁcation of calibration using several VOIs placed
in the uniform background compartment. Results are
(automatically) compared with reference values to assess
if scanner performance meets the harmonizing quality
standards. All QC experiments are centrally analyzed
at the EARL headquarters and results are stored in
a database. An internet-based submission procedure
has been set up so that imaging sites can upload
QC experiment results to EARL headquarters.
A pilot phase of this accreditation program linked
to the EORTC 22071–24071 trial commenced in October
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2010. It included 11 sites and a total of 12 PET/CT
systems. All QC experiments were executed over a
3-month period and data were provided to the EARL
headquarters. Initial central analysis showed that two
out of eleven imaging sites needed to recalibrate
their PET/CT systems and adjust image reconstruction
settings. Following these corrective actions, all sites met
minimal and harmonizing quantitative standards, and
received approval. Minor start-up issues such as reading
image ﬁles, ambiguities with respect to reporting times,
phantom availability, and data entry issues were resolved
within the three-month time frame.
3. CT imaging
CT is a widely available imaging technique with a high
spatial resolution, for which tumor evaluation criteria 9
have been well established. For many solid tumors, CT re-
mains the main imaging method for the assessment of
(anatomic) tumor response. Because of the wide and
frequent use of CT for morphologic oncologic staging in
daily clinical routine, it would appear almost redundant
to discuss the need for standardization. However, just
because of its wide routine application, it is not implicit
that image acquisition and quantiﬁcation technique are
the same and replicable. Delineation of tumor borders
is not only determined by factors related to tumor type
and tumor growth but also to the CT scanning technique.
This makes the need for standardization immediately
apparent. Factors determining image quality in CT
are image acquisition and reconstruction parameters
as well as contrast injection parameters that describe
how intravenous contrast agents are administered.
These factors determine not only spatial resolution but
also tumor-tissue contrast which crucially affects any
quantiﬁcation.
CT performance has advanced rapidly. The scan range
that can be covered at minimum section thickness within
a ﬁxed scan duration has doubled every two years
for more than a decade. For almost ten years now,
isotropic resolution is a fact with modern CT scanners.
This means that image quality is no longer higher
for axial sections than for coronal or sagittal sections.
Submillimeter resolution in any imaging plane is
nowadays considered standard. While CT is able to
provide detailed tumor assessment in three dimensions,
most measurement criteria are still based on two-
dimensional measurements in the axial plane. This does
not reﬂect the capabilities of modern technology and
the general availability of 16-slice CT (or even more)
scanners. Volumetric evaluation is possible for lung
nodules and becomes an option also for lymph nodes
and lesions in other organs. However, accuracy and
reproducibility of results strongly depend on the semi-
automated software used for analysis and need to be
standardized for multicenter trials.
Since the intrinsic tissue contrast in CT is minimal due
to X-ray attenuation, the differential increase in attenu-
ation due to the intravenously injected contrast material
is crucial for tumor delineation. With modern CT (>16
detector rows), scanning of the chest or the abdomen
in less than 10 s has become possible and allows for
submillimeter isotropic volumetric data acquisition dur-
ing speciﬁc phases of perfusion (arterial, portal venous,
equilibrium, etc.) after IV contrast injection. Depending
on tumor biology, the phase in which the tumor is
best delineated varies. Standardization of the acquisition
phase is therefore mandatory for large multicenter trials
to ensure comparability of results. CT perfusion imaging
is an emerging technology that can be used to derive
changes in blood ﬂow, blood volume, mean transit time
and permeability. CT perfusion is therefore able to
provide functional information about the microvascular
environment and reﬂects angiogenesis and leakiness of
the capillary system. Software tools for deriving these
functional parameters are frequently vendor-speciﬁc and
lack comparability. To be used in multicenter clinical
trials, standardization is required. This includes the use
of identical contrast injection protocols, identical scan
sequences, and identical evaluation software to ensure
comparability of the quantiﬁed results across sites.
4. Standardizing MRI readouts for use in
multicenter trials
Unlike CT where tissue contrast is dependent on its X-ray
attenuation by virtue of its density, the mechanisms
used to generate tissue contrast in MRI are complex
and depend on the relaxivity of free water within
tissues determined by their molecular interactions. A
number of hardware (static magnetic ﬁeld strength,
radiofrequency [rf] signal transmitters, rf signal receivers,
magnetic ﬁeld gradients) as well as software (length,
amplitude, duration, spacing of the rf pulses and their
sequence) parameters will affect the emitted signal
strength, and hence tissue contrast. Primarily, the
instrumentation itself determines the received signal
and standardization of readouts will need to take
account of static ﬁeld strength, particularly with a variety
ranging from 0.5Tesla (T) to 3.0T and now even 7.0T
available for human imaging.
Currently the quantiﬁed parameters most commonly
used in oncology as biomarkers of treatment response
are those reporting on lesion water content (T2 [trans-
verse relaxation time] relaxivity), vascularity (derived
from dynamic contrast enhanced examinations) and
tissue cellular content (derived from diffusion-weighted
sequences). The contrast mechanisms generating these
parameters are not ﬁeld-strength dependent. However,
their reproducibility, particularly in a multicenter setting,
can be extremely variable with quoted values of
15−40% for DCE, and 7−15% for the apparent diffusion
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coefﬁcient (ADC). 10 Reproducibility is affected by data
acquisition parameters (signal-to-noise ratio [SNR] tem-
poral sampling rate for DCE-MRI; number and value of
b-values for ADC) and by methodology used for data
processing/analysis.
4.1. Data acquisition
The greater the SNR from a lesion, the more likely the
measurement is to be reproducible. Use of a high static
ﬁeld strength (1.5T or 3T), optimal coil combinations for
signal reception and best choice of sequence parameters,
repetition time, echo time, ﬂip angle, acquisition matrix,
ﬁeld of view, slice thickness) is required to achieve
this. In a multicenter trial these parameters need to
be standardized across the portfolio of scanners to
be used, and regular QA needs to be done using
test objects to ensure that SNR is maintained within
acceptable limits without unwanted artifacts. For DCE-
MRI the temporal sampling rate will affect accuracy of
the derived parameters and hence their reproducibility.
An optimal sampling rate is a compromise between
spatial and temporal resolution which is affected by the
minimum repetition time of the sequence; usually rates
of around 3−4 seconds may be achieved for 15−20 slices
with a 0.6×0.6×5mm spatial resolution. With diffusion-
weighted imaging echo-planar readouts are preferred
over turbo-spin-echo techniques as they are rapid and
effectively “freeze” motion, although distortion from
ﬁeld inhomogeneities and eddy currents can limit their
interpretation. Use of a low b-value (a minimum of
100mm2/s to avoid variable microperfusion effects seen
at lower b-values) and a high b-value (~1000mm2/s)
enables calculation of the rate of decay of signal intensity
between them which represents the apparent diffusion
coefﬁcient. Optimal choice of b-values depends on the
ADC of the tissue itself and needs to be established and
agreed prior to trial commencement.
4.2. Data analysis
The methodology used for processing the acquired signal
introduces a further source of variation. Contrast to
noise critically affects lesion conspicuity and determines
region of interest delineation. For DCE-MRI data the
arterial input function (AIF) may be measured on
an individual basis or use of a population-based AIF
may be preferred. The latter has the advantage of
better repeatability and reduces measurement error. For
DW-MRI, multiple b-values in the acquisition enable
use of a model that ﬁts the signal decay (bi- or multi-
exponential) and potentially yields a more accurate and
reproducible result. The number and range of derived ap-
parent diffusion coefﬁcient values in the included pixels
critically affects data interpretation because threshold
values are commonly used to differentiate tumour from
non-tumour tissues. Therefore choice of sequence for
lesion delineation, methodology of delineation (manual,
automated, semi-automated), model used to ﬁt the data
and threshold values to be used need to be clariﬁed and
approved at the outset for individual trials.
5. Online central review and quality control during
a trial
From the pilot described above, as well as from ongoing
multicenter studies that include imaging, we have
learned that centralized prospective QC of the (patient’s)
scans and prompt feedback to the imaging sites is
paramount to ensure successful execution of the imaging
guidelines and achieving the trial protocol objectives. 11
There is an increased susceptibility to image quality
defects soon after start of a multicenter imaging trial
and after the addition of new imaging equipment. 12 The
EORTC IG started a QC/QA program and will monitor
imaging guidelines compliance across the different
imaging modalities on an ongoing basis. For some
multicenter clinical trials the EORTC IG has produced
standardized or harmonized imaging protocols for
acquisition and reconstruction parameters and QC/QA of
scans. An additional goal of the EORTC IG is to organize
and execute the standardization of DWI-MRI scans across
imaging centers, more speciﬁcally within the chest and
abdomen under the QuIC-ConCePT program (cf section
on Quantitative Imaging in Cancer: Connecting Cellular
Processes with Therapy).
Over the past few years,members of the EORTC IG have
been involved in several studies, among which were:
• The H10 EORTC/GELA/IIL randomized Intergroup trial
on early FDG-PET scan guided treatment adaptation
versus standard combined modality treatment in
patients with supradiaphragmatic stage I/II Hodgkin’s
lymphoma (EORTC 20051).
• A randomized double blind phase III trial of pazopanib
versus placebo in patients with soft tissue sarcoma
whose disease has progressed during or following prior
therapy (EORTC 62072).
• Randomized trial assessing the signiﬁcance of Bevaci-
zumab in recurrent grade II and grade III gliomas − the
TAVAREC trial (EORTC 26091).
• Phase III trial on concurrent and adjuvant temozolo-
mide chemotherapy in non-1p/19q deleted anaplastic
glioma − the CATNON intergroup trial (EORTC 26053).
6. Web-based analysis for multiple readers: the
EORTC Imaging Platform
Although the studies mentioned above have demon-
strated the feasibility of performing centralized review
of imaging during the execution of a clinical trial there
remains a need for improving image data transfer
and central image viewing/interpretation. The EORTC
Imaging Platform in collaboration with Keosys, an SME
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specializing in medical imaging IT applied to clinical
research and medical diagnostics, was established to
enable the development of a variety of image interpreta-
tion and analysis methodologies that suit multimodality
image data and image assessment requirements for
a variety of trial designs. This platform supports
both nuclear medicine and radiology data sets that
can be analyzed for staging, evaluation of response,
prediction of response, and correlation with pathology.
This level of incorporation of imaging technologies into
the framework of clinical trials could fully exploit the
potential of imaging for optimizing treatment so that
the appropriate treatments can be delivered to patients
who are most likely to beneﬁt. Use of imaging to aid in
decision making during early drug development trials
should accelerate patients’ access to more effective
therapy. As part of this long-term goal, the validation of
functional biomarkers is the key.
7. QuIC-ConCePT − Quantitative Imaging in
Cancer: Connecting Cellular Processes with
Therapy
The Innovative Medicines Initiative (IMI) was set
up to support faster discovery and development of
better medicines for patients and to enhance Europe’s
competitiveness by ensuring a dynamic European bio-
pharmaceutical sector. The QuIC-ConCePT consortium
was assembled to answer the IMI call for Imaging
Biomarkers (IBs) for anticancer drug development.
A major objective of QuIC-ConCePT is to qualify IBs
of tumor cell proliferation, apoptosis, and necrosis that
will allow drug developers to reliably demonstrate the
modulation of these pathologic processes in patients
with malignant tumors inclinical trials. QuIC-ConCePT
has the unique opportunity to deliver tools which could
markedly improve drug development and beneﬁt cancer
patients not only in Europe but worldwide.
It is envisioned that by 2016, drug developers will
be able to incorporate IBs quantiﬁed and validated
by the QuIC-ConCePT program in Phase I trials of
investigational therapies and be conﬁdent that the IBs
are technically valid, that a measured change in the IBs
faithfully reﬂects the desired change in the underlying
tumor pathology, and that the IBs can be readily deployed
in multiple cancer centers in a robust, consistent, ethical,
and cost-effective way acceptable to the patients.
IBs of tumor cell proliferation and necrosis will
be developed from 3′-deoxy-3′-[18F]ﬂuorothymidine (FLT)
PET and apparent diffusion coefﬁcient (ADC) of water
protons measured by MRI, respectively. Recognizing
that the science around apoptosis tracers is less
secure, studies will initially focus on the novel isatin-5
sulfonamide PET tracer [18F]ICMT-11 (ICMT-11), but the
work plan allows additional or alternative apoptosis
tracers to be utilized in later years.
A more exploratory objective of QuIC-ConCePT in-
cludes a portfolio of highly innovative approaches to
devise, evaluate, and introduce IBs of invasion and
metastasis.
Overall, QuIC-ConCePT will be delivered using a
creative and comprehensive portfolio of animal, human,
image analysis, and regulatory work. The project plans to
deliver image acquisition and analysis protocols which
are technically valid, standardized, and suitable for
multicenter use. The plan is to evaluate these IBs, assess
their reproducibility, effects of intervention, timing, dose–
response, and imaging–histopathology correlation in
animals and patients.
Platforms for data acquisition, analysis, and dis-
semination will be standardized and integrated across
the consortium in order to support this project, and
an approach based on data collection, transfer, and
archiving mechanisms will be adopted.
8. Imaging in radiation oncology
Although the imaging methods used in radiation
oncology are the same as used for diagnostic questions,
aims and scope of imaging in radiation oncology differ
substantially from diagnostic applications in medical
oncology. Oncological image data are the treatment
tools in the hand of the radiation oncologist guiding
indications, target volume selection and delineation,
normal tissue identiﬁcation, response prediction and
monitoring, and they provide relevant post-treatment
information on local tumor control and normal tissue
reactions. In addition, information regarding biological
processes such as hypoxia, metabolism, etc. that is
available from molecular and functional imaging can
potentially be used to customize radiation therapy
planning. Imaging in radiation oncology is therefore an
additional focus of the EORTC IG. In close collaboration
with the Radiation Oncology Group and the disease-
oriented Groups, the EORTC IG assists the development
of radiotherapy protocols related to imaging. Beyond this,
imaging questions in radiotherapy will be addressed in
imaging trials which are companion protocols to the
EORTC studies including radiotherapy. Furthermore, the
infrastructural possibilities are presently being created
for research on imaging changes due to tumor response
and normal tissue reactions after radiation therapy in
relation to dose distributions and clinical data.
9. NCI–EORTC collaboration in clinical imaging
The Division of Cancer Treatment and Diagnosis
(DCTD) at the National Cancer Institute (NCI) in
the United States has a long and productive history
of collaboration with the EORTC on imaging issues
in clinical trials. In particular, the Cancer Imaging
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Program (http://imaging.cancer.gov) within DCTD has
been working closely with the EORTC both on RECIST as
well as imaging activities in EORTC trials. Collaborations
have included multiple meetings and strategy sessions
both in the USA and in Brussels over the past several
years, as well as an extended visit to Brussels during
the time when the EORTC Imaging Program was
conceived and developed. In these ongoing interactions,
the Cancer Imaging Program has shared its experiences
with developing and managing clinical trials in imaging
in the NCI cooperative group system. This NCI–EORTC
collaboration aims to enhance the standardization of
imaging-related processes in order to increase the utility
of data from both NCI and EORTC trials evaluating
molecular and functional imaging tools to improve
cancer diagnosis, molecular stratiﬁcation of tumor
subtypes, as well as improve response assessment.
Highlights of these ongoing discussions include
activities to enhance interaction between the oncologists
and imagers during study concept and design and de-
velopment of successful strategies for either primary or
secondary imaging aims in EORTC trials. Issues and pro-
cesses regarding site qualiﬁcation (http://www.acrin.org/
CORELABS/NCICQIEQUALIFICATIONPROGRAM.aspx), the
establishment and operations related to imaging core
labs with regard to imaging acquisition SOPs, central
review as well as the evaluation process for imaging tools
are addressed on an ongoing basis.
10. Summary
The EORTC recognizes the crucial role of imaging in
clinical trials. As we advance towards a personalized
medicine approach, selection of the most appropriate
imaging modality for a speciﬁc task will be vital for
diagnosis, stratiﬁcation, treatment response or treatment
efﬁcacy, toxicity assessment, and treatment outcome
measures (progression-free survival). The EORTC there-
fore established the EORTC IG to enhance clinical
imaging expertise and develop multicenter imaging
QA/QC programs and guidelines. To complement this
effort, the EORTC is investing in and setting up a web-
based system for central image review, analysis, and
reporting, and it participates in a European consortium
for the implementation of various imaging biomarkers
as validated and approved tools in drug development
trials.
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